193 related articles for article (PubMed ID: 9230823)
1. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.
Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K
Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823
[TBL] [Abstract][Full Text] [Related]
2. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
LeBlanc RP
Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension.
Schuman JS
Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S27-37. PubMed ID: 8970247
[TBL] [Abstract][Full Text] [Related]
4. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group.
Katz LJ
Am J Ophthalmol; 1999 Jan; 127(1):20-6. PubMed ID: 9932994
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III.
Serle JB
Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S39-47. PubMed ID: 8970248
[TBL] [Abstract][Full Text] [Related]
6. Brimonidine tartrate: a one-month dose response study.
Derick RJ; Robin AL; Walters TR; Barnebey HS; Choplin N; Schuman J; Kelley EP; Chen K; Stoecker JF
Ophthalmology; 1997 Jan; 104(1):131-6. PubMed ID: 9022117
[TBL] [Abstract][Full Text] [Related]
7. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies.
Walters TR
Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S19-26. PubMed ID: 8970246
[TBL] [Abstract][Full Text] [Related]
8. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension.
Adkins JC; Balfour JA
Drugs Aging; 1998 Mar; 12(3):225-41. PubMed ID: 9534022
[TBL] [Abstract][Full Text] [Related]
9. A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Apraclonidine Primary Therapy Study Group.
Stewart WC; Laibovitz R; Horwitz B; Stewart RH; Ritch R; Kottler M
Arch Ophthalmol; 1996 Aug; 114(8):938-42. PubMed ID: 8694728
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of apraclonidine as an adjunct to timolol therapy. Apraclonidine Adjunctive Therapy Study Group.
Stewart WC; Ritch R; Shin DH; Lehmann RP; Shrader CE; van Buskirk EM
Arch Ophthalmol; 1995 Mar; 113(3):287-92. PubMed ID: 7887841
[TBL] [Abstract][Full Text] [Related]
11. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment.
Greenfield DS; Liebmann JM; Ritch R
J Glaucoma; 1997 Aug; 6(4):250-8. PubMed ID: 9264305
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure. A six month, evaluator masked, multicentre study in Europe.
García-Sánchez J; Rouland JF; Spiegel D; Pajic B; Cunliffe I; Traverso C; Landry J
Br J Ophthalmol; 2004 Jul; 88(7):877-83. PubMed ID: 15205229
[TBL] [Abstract][Full Text] [Related]
13. The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine.
Nordlund JR; Pasquale LR; Robin AL; Rudikoff MT; Ordman J; Chen KS; Walt J
Arch Ophthalmol; 1995 Jan; 113(1):77-83. PubMed ID: 7826297
[TBL] [Abstract][Full Text] [Related]
14. Comparison of apraclonidine and timolol in chronic open-angle glaucoma. A three-month study.
Nagasubramanian S; Hitchings RA; Demailly P; Chuniaud M; Pannarale MR; Pecori-Giraldi J; Stodtmeister R; Parsons DG
Ophthalmology; 1993 Sep; 100(9):1318-23. PubMed ID: 8371918
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group.
Silver LH
Am J Ophthalmol; 1998 Sep; 126(3):400-8. PubMed ID: 9744373
[TBL] [Abstract][Full Text] [Related]
16. Effect of brimonidine tartrate on ocular hemodynamic measurements.
Lachkar Y; Migdal C; Dhanjil S
Arch Ophthalmol; 1998 Dec; 116(12):1591-4. PubMed ID: 9869786
[TBL] [Abstract][Full Text] [Related]
17. Effects of brimonidine 0.2% on blue-yellow perimetry of glaucomatous patients.
Mastropasqua L; Ciancaglini M; Carpineto P; Zuppardi E; Falconio G; Gallenga PE
Acta Ophthalmol Scand Suppl; 1998; (227):36. PubMed ID: 9972338
[TBL] [Abstract][Full Text] [Related]
18. Effects of brimonidine on aqueous humor dynamics in human eyes.
Toris CB; Gleason ML; Camras CB; Yablonski ME
Arch Ophthalmol; 1995 Dec; 113(12):1514-7. PubMed ID: 7487618
[TBL] [Abstract][Full Text] [Related]
19. Brimonidine in the prevention of intraocular pressure elevation following argon laser trabeculoplasty.
David R; Spaeth GL; Clevenger CE; Perell HF; Siegel LI; Henry JC; Stiles MC; Passo MS; Stamper RL; Walt JG
Arch Ophthalmol; 1993 Oct; 111(10):1387-90. PubMed ID: 8105773
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty.
Barnebey HS; Robin AL; Zimmerman TJ; Morrison JC; Hersh SB; Lewis RA; Coleman AL; Cinotti DJ; Walt J; Chen KS
Ophthalmology; 1993 Jul; 100(7):1083-8. PubMed ID: 8100625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]